Sales increased for the quarter 8% to $73 million, but unfortunately that came in at the low end of the guidance. And that growth is after the first quarter's disastrous $68 million performance. Losses decreased to $0.45 sequentially, but the company acknowledged that it won't hit its guidance target for year-over-year annual growth and refused to give additional guidance.
In this video, health-care analyst David Williamson discusses these results and key conference-call takeaways for investors in Dendreon, why they should be concerned about increasing competition, and why time is not on their side.